PARP1 and neoplasm: Olaparib (AZD2281) is a potent oral PARP-1 inhibitor.8 Despite a variety of pre-clinical studies showing increased sensitivity of tumours to radiation by olaparib,5,9–11 the effect of olaparib on the response of normal tissues to radiation has been little studied in vivo.